MedTrace Logo

A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects

NCT05560360 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-02-02

No results posted yet for this study

Summary

This study used a single-dose, open and fixed sequence design to compare the pharmacokinetics in healthy subjects.

Conditions

  • B-cell Tumors

Interventions

DRUG

SHR1459 tablet

100 mg/tablet; administered orally

DRUG

Efavirenz tablet

600 mg/tablet; administered orally

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-04
Primary Completion
2022-12-02
Completion
2023-01-27

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05560360 on ClinicalTrials.gov